PRISM MEDICO AND PHARMACY LIMITED

CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com
Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030

Date: 12.08.2026

To, Department of Corporate Services, **BSE LIMITED** P. J. Towers, Dalal Street, Mumbai, Maharashtra-400001. **ISIN : INE730E01016** **Scrip Code: 512217**	To, Listing Department, **Metropolitan Stock Exchange of India Limited (MSEI)** Vibgyor Towers, 4th Floor, Plot Number C 62, G - Block, Opposite Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai, Maharashtra-400098. **SYMBOL: PRISMMEDI**

Subject: Outcome of the Board Meeting - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today (i.e. 12th August, 2026) which commenced at 01:30 P.M. and concluded at 03:30 P.M. have inter alia approved the following:

- The Board considered and approved the Unaudited Standalone Financial Results of the company for the quarter ended 30th June, 2026 alongwith the Limited Review Report duly signed by the Auditors of the company.

You are requested to kindly take the same on record and oblige.

Thanking You.

Yours Truly,
FOR PRISM MEDICO AND PHARMACY LIMITED

Davender Singh

DAVENDER SINGH
DIRECTOR
DIN: 09447213

PRISM MEDICO AND PHARMACY LIMITED

CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com
Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030

TEXT OF RESOLUTION PASSED AT A DULY CONVENED MEETING OF THE BOARD OF DIRECTORS OF THE COMPANY HELD DURING THE FINANCIAL YEAR 2026-2027 ON WEDNESDAY, THE 12TH DAY OF AUGUST, 2026 AT 01:30 P.M. AT THE REGISTERED OFFICE OF THE COMPANY SITUATED AT SUKETI ROAD, KALA AMB, SIRMAUR, HIMACHAL PRADESH-173030.

2. TO APPROVE THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026.

The Board discussed and then passed the following resolution:

"**RESOLVED THAT** pursuant to the applicable provisions of the Companies Act, 2013 and Rules made thereunder (including any statutory modification or re-enactment(s) thereof for the time being in force) and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 the unaudited standalone financial results of the company for the quarter ended 30th June, 2026 as reviewed by the Audit Committee and tabled before the Board be and hereby approved."

"**RESOLVED FURTHER THAT** Mr. Davender Singh, Director of the company be and is hereby authorized to sign the said statement of accounts and to do all such acts, deeds, and things as may be necessary to give effect to the above said resolution."

CERTIFIED TO BE TRUE COPY
FOR PRISM MEDICO AND PHARMACY LIMITED

DAVENDER SINGH
DIRECTOR (DIN: 09447213)
VILLAGE DHALOUR, P.O. SHERPUR,
SALKHANI, SARAWAN, YAMUNANAGAR,
HARYANA-133206.

Garg Mendiratta & Associates
CHARTERED ACCOUNTANTS
(A PEER REVIEWED FIRM)

59, Gobind Nagar,
Ambala Cantt - 133 001 (Haryana)
Tel. : 0171-4055565 (O), 2650065 (R)
Mobile : 94160-20565, 70157-44428
mail : gmca123@rediffmail.com
gmca123@gmail.com

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Standalone Un-Audited Financial Result of ***M/s. Prism Medico And Pharmacy Ltd*** having its Regd. Office at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh – 173030 for the **Quarter ended 30th June 2026** ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements). Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For GARG MENDIRATTA & ASSOCIATES.
CHARTERED ACCOUNTANTS.

GARG MENDIRATTA & ASSOCIATES
CHARTERED ACCOUNTANTS
AMBALA CANTT.

Jaspreet Singh

CA JASPREET SINGH MENDIRATTA
M. No 097687
Date: 12.08.2026
UDIN: 26097687MPULZJ1253

PRISM MEDICO AND PHARMACY LIMITED

CIN: L24100HP2002PLC009299; EMAIL ID: INVESTORGRIEVANCEWMCL@GMAIL.COM

REGISTERED OFFICE: SUKETI ROAD, KALA AMB, SIRMAUR, HIMACHAL PRADESH-173030

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER YEAR ENDED 30TH JUNE 2026 (In Lakhs)

	PARTICULARS	Quarter Ended			Year to date 30.06.2026	Year Ended (Audited)	Year Ended (Audited)
		30.06.2026	31.03.2026	30.06.2025		31.03.2026	31.03.2025
I	**Income**						
	Revenue from operations	-	28.14	158.87	-	244.34	63.19
	Other income	9.06	0.21	0.04	9.06	2.61	1.65
	Total income from operations	**9.06**	**28.35**	**158.91**	**9.06**	**246.95**	**64.84**
II	**Expenses**						
	Cost of material consumed	-	21.53	85.75	-	156.88	44.85
	Change in inventories	-	-	-	-	-	-
	Employee benefit expenses	1.77	2.69	0.95	1.77	6.03	4.26
	Finance costs	0.02	0.03	-	0.02	0.33	0.17
	Depreciation and amortization expenses	0.09	0.06	0.13	0.09	0.35	0.42
	Other expenses	13.02	16.33	7.01	13.02	40.41	21.72
	Total expenses	**14.89**	**40.64**	**93.84**	**14.89**	**203.99**	**71.42**
III	**Profit/(Loss) before exceptional items and tax**	**(5.83)**	**(12.29)**	**65.07**	**(5.83)**	**42.96**	**(6.58)**
IV	**Exceptional items**	-	-	-	-	-	-
V	**Profit/(Loss) before tax**	**(5.83)**	**(12.29)**	**65.07**	**(5.83)**	**42.96**	**(6.58)**
VI	**Tax expenses**						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	11.78	0.66	-	(11.12)	1.71
	b) Mat Credit	-	-	-	-	-	-
VII	**Net Profit/(Loss) for the period/year**	**(5.83)**	**(24.07)**	**65.73**	**(5.83)**	**31.84**	**(4.87)**
VIII	**Other comprehensive income (net of tax)**						
	Items that will not be reclassified to profit or loss:						
	i) Remeasurement of post employment benefit obligations	-	-	-	-	-	-
	ii) Prior period income adjustment (Net of tax)	-	-	-	-	-	-
	Total other comprehensive income	-	-	-	-	-	-
IX	**Total comprehensive income for the period/year (VII+VIII)**	**(5.83)**	**(24.07)**	**65.73**	**(5.83)**	**31.84**	**(4.87)**
X	**Paid-up equity share capital (face value of the share shall be indicated)**	**1,356.34**	**606.34**	**606.34**	**606.34**	**606.34**	**606.34**
XI	**Other equity (excluding revaluation reserve)**	1,803.95	934.78	968.67	1,803.95	934.78	902.94
XII	**EPS in Rs. (Face Value of Rs.10/- each)***						
	- Basic	(0.0400)	(0.0040)	0.0108	(0.0010)	0.0053	(0.0008)
	- Diluted	(0.0400)	(0.0040)	0.0108	(0.0010)	0.0053	(0.0008)

Notes:

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 12.08.2026 after being reviewed by the Audit Committee.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. The company is having single segment in accordance with IND AS 108 "Operating Segments" and therefore segment reporting is not applicable to the company.

FOR AND ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LIMITED

DAVENDER SINGH
DIRECTOR
DIN: 09447213

Place: KALA AMB, HIMACHAL PRADESH.
Date: 12TH AUGUST, 2026.